title: Induction of anomalous killing activity from antigen-specific CTL clones by adding high doses of human recombinant interleukin 2.
abstract: Four out of six long-term murine cytotoxic T lymphocyte (CTL) clones specific for trinitrophenyl (TNP)-modified spleen cells could develop an anomalous cytotoxicity against syngeneic and allogeneic tumor cells upon stimulation with TNP-modified spleen cells and high doses of human recombinant interleukin 2 (rIL-2). On FACS analysis, hyperactivated CTLs were positive for Thy-1, Ly 2 and LFA-1, but negative for L3T4 and asialo GM1. The staining profile of the cells with each antibody indicated that the CTL clones consisted of just one cell type. Monoclonal anti-Ly 2.2 and anti-LAA (lymphokine-activated cell-associated antigen) antibodies inhibited cytolysis of CTL and hyperactivated CTL clones against TNP-modified spleen cells, but failed to inhibit the anomalous killing of the hyperactivated CTL. The cold target competition test suggested the degeneracy of antigen specificity. The present study demonstrated that the CTL clone acquired a new specificity for tumor target cells upon stimulation with a high dose of rIL-2.
authors.affiliation: Division of Radiation Health, National Institute of Radiological Sciences, Chiba, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Moriyama
authors.forename: G
authors.initials: G
authors.lastname: Suzuki
authors.forename: I
authors.initials: I
authors.lastname: Nakao
authors.forename: S
authors.initials: S
authors.lastname: Aizawa
authors.forename: K
authors.initials: K
authors.lastname: Okumura
authors.forename: T
authors.initials: T
authors.lastname: Nishimura
authors.forename: F
authors.initials: F
authors.lastname: Takaku
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation / Q000032:analysis; D000950:Antigens, Ly / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D002999:Clone Cells; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D007111:Immunity, Cellular / Q000187:drug effects; D007376:Interleukin-2 / Q000008:administration & dosage*; D008213:Lymphocyte Activation; D016169:Lymphocyte Function-Associated Antigen-1; D051379:Mice; D011994:Recombinant Proteins / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014301:Trinitrobenzenes / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D000950:Antigens, Ly; D000954:Antigens, Surface; D007376:Interleukin-2; D016169:Lymphocyte Function-Associated Antigen-1; D011994:Recombinant Proteins; D014301:Trinitrobenzenes